- Home
- FGB vs ONCY Comparison
FGB vs ONCY Comparison
Compare FGB & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- ONCY
- Stock Information
- Founded
- FGB 2007
- ONCY 1998
- Country
- FGB United States
- ONCY Canada
- Employees
- FGB N/A
- ONCY N/A
- Industry
- FGB Finance/Investors Services
- ONCY Pharmaceuticals and Biotechnology
- Sector
- FGB Finance
- ONCY Health Care
- Exchange
- FGB Nasdaq
- ONCY Nasdaq
- Market Cap
- FGB 58.9M
- ONCY 49.1M
- IPO Year
- FGB N/A
- ONCY 1999
- Fundamental
- Price
- FGB $4.01
- ONCY $0.35
- Analyst Decision
- FGB
- ONCY Strong Buy
- Analyst Count
- FGB 0
- ONCY 4
- Target Price
- FGB N/A
- ONCY $4.33
- AVG Volume (30 Days)
- FGB 53.0K
- ONCY 847.4K
- Earning Date
- FGB 01-01-0001
- ONCY 05-14-2025
- Dividend Yield
- FGB 8.92%
- ONCY N/A
- EPS Growth
- FGB N/A
- ONCY N/A
- EPS
- FGB N/A
- ONCY N/A
- Revenue
- FGB N/A
- ONCY N/A
- Revenue This Year
- FGB N/A
- ONCY N/A
- Revenue Next Year
- FGB N/A
- ONCY N/A
- P/E Ratio
- FGB N/A
- ONCY N/A
- Revenue Growth
- FGB N/A
- ONCY N/A
- 52 Week Low
- FGB $2.85
- ONCY $0.33
- 52 Week High
- FGB $3.74
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- FGB 51.99
- ONCY 25.67
- Support Level
- FGB $3.97
- ONCY $0.33
- Resistance Level
- FGB $4.11
- ONCY $0.45
- Average True Range (ATR)
- FGB 0.09
- ONCY 0.04
- MACD
- FGB 0.00
- ONCY -0.01
- Stochastic Oscillator
- FGB 25.00
- ONCY 8.10
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.